Mario Balsa, Medical Oncologist at Hospital Clínic de Barcelona, shared on X:
“How do we treat melanoma when we are treating for two?
Excellent practical session by Jessica Borgers on melanoma and pregnancy.
Key takeaways:
- Evidence remains scarce
- ICI may disrupt fetal-maternal tolerance: prematurity/IUGR concern
- Anti-LAG3 pregnancy data: essentially none
- BRAF/MEK: very limited evidence; consider only case by case
- After high-risk adjuvant therapy: ideally wait ~3 years
- After neoadjuvant ICI+MPR? Maybe shorter
Personalized oncology means treating not one patient, but two timelines at once!”
